ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Antisense Oligonucleotides (ASOs) Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: November 2025
|
Report Code: QYRE-Auto-0F17682
Home | Market Reports | Science| Biological Sciences
Global Antisense Oligonucleotides ASOs Drugs Market Research Report 2024
BUY CHAPTERS

Global Antisense Oligonucleotides (ASOs) Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-0F17682
Report
November 2025
Pages:150
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Lonis Pharmaceuticals
Novartis
Sanofi
GSK
Sarepta
Kastle
Biogen

Antisense Oligonucleotides (ASOs) Drugs Market

The global Antisense Oligonucleotides (ASOs) Drugs market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Drugs--Antisense oligonucleotides (ASO, Antisense oligonucleotides) are chemically modified single-stranded DNA or RNA molecule fragments, usually 15-30 nucleotides in length, that interact with endogenous molecules through Watson-Crick base pairing rules. Specific binding to sexual mRNA targets. ASO includes antisense RNA (asRNA) and antisense DNA (asDNA).
From a downstream perspective, Hospital accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Antisense Oligonucleotides (ASOs) Drugs leading manufacturers including Lonis Pharmaceuticals, Novartis, Sanofi, GSK, Sarepta, Kastle, Biogen, etc., dominate supply; the top five capture approximately % of global revenue, with Lonis Pharmaceuticals leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Antisense Oligonucleotides (ASOs) Drugs market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Antisense Oligonucleotides (ASOs) Drugs Market Report

Report Metric Details
Report Name Antisense Oligonucleotides (ASOs) Drugs Market
Segment by Type
  • Cleave and Degrade
  • Splice
Segment by Application
  • Hospital
  • Clinic
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Lonis Pharmaceuticals, Novartis, Sanofi, GSK, Sarepta, Kastle, Biogen
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Antisense Oligonucleotides (ASOs) Drugs study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
  • Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 15: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Antisense Oligonucleotides (ASOs) Drugs Market report?

Ans: The main players in the Antisense Oligonucleotides (ASOs) Drugs Market are Lonis Pharmaceuticals, Novartis, Sanofi, GSK, Sarepta, Kastle, Biogen

What are the Application segmentation covered in the Antisense Oligonucleotides (ASOs) Drugs Market report?

Ans: The Applications covered in the Antisense Oligonucleotides (ASOs) Drugs Market report are Hospital, Clinic

What are the Type segmentation covered in the Antisense Oligonucleotides (ASOs) Drugs Market report?

Ans: The Types covered in the Antisense Oligonucleotides (ASOs) Drugs Market report are Cleave and Degrade, Splice

1 Study Coverage
1.1 Introduction to Antisense Oligonucleotides (ASOs) Drugs: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Antisense Oligonucleotides (ASOs) Drugs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Cleave and Degrade
1.2.3 Splice
1.3 Market Segmentation by Application
1.3.1 Global Antisense Oligonucleotides (ASOs) Drugs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Antisense Oligonucleotides (ASOs) Drugs Revenue Estimates and Forecasts 2020-2031
2.2 Global Antisense Oligonucleotides (ASOs) Drugs Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Antisense Oligonucleotides (ASOs) Drugs Sales Estimates and Forecasts 2020-2031
2.4 Global Antisense Oligonucleotides (ASOs) Drugs Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Antisense Oligonucleotides (ASOs) Drugs Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Antisense Oligonucleotides (ASOs) Drugs Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Cleave and Degrade Market Size by Manufacturers
3.5.2 Splice Market Size by Manufacturers
3.6 Global Antisense Oligonucleotides (ASOs) Drugs Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Antisense Oligonucleotides (ASOs) Drugs Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Antisense Oligonucleotides (ASOs) Drugs Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Antisense Oligonucleotides (ASOs) Drugs Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Antisense Oligonucleotides (ASOs) Drugs Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Antisense Oligonucleotides (ASOs) Drugs Sales and Revenue by Type (2020-2031)
6.4 North America Antisense Oligonucleotides (ASOs) Drugs Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Antisense Oligonucleotides (ASOs) Drugs Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Antisense Oligonucleotides (ASOs) Drugs Sales and Revenue by Type (2020-2031)
7.4 Europe Antisense Oligonucleotides (ASOs) Drugs Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Antisense Oligonucleotides (ASOs) Drugs Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Antisense Oligonucleotides (ASOs) Drugs Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Antisense Oligonucleotides (ASOs) Drugs Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Antisense Oligonucleotides (ASOs) Drugs Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Antisense Oligonucleotides (ASOs) Drugs Sales and Revenue by Type (2020-2031)
9.4 Central and South America Antisense Oligonucleotides (ASOs) Drugs Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Antisense Oligonucleotides (ASOs) Drugs Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Antisense Oligonucleotides (ASOs) Drugs Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Antisense Oligonucleotides (ASOs) Drugs Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Antisense Oligonucleotides (ASOs) Drugs Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Lonis Pharmaceuticals
11.1.1 Lonis Pharmaceuticals Corporation Information
11.1.2 Lonis Pharmaceuticals Business Overview
11.1.3 Lonis Pharmaceuticals Antisense Oligonucleotides (ASOs) Drugs Product Models, Descriptions and Specifications
11.1.4 Lonis Pharmaceuticals Antisense Oligonucleotides (ASOs) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Lonis Pharmaceuticals Antisense Oligonucleotides (ASOs) Drugs Sales by Product in 2024
11.1.6 Lonis Pharmaceuticals Antisense Oligonucleotides (ASOs) Drugs Sales by Application in 2024
11.1.7 Lonis Pharmaceuticals Antisense Oligonucleotides (ASOs) Drugs Sales by Geographic Area in 2024
11.1.8 Lonis Pharmaceuticals Antisense Oligonucleotides (ASOs) Drugs SWOT Analysis
11.1.9 Lonis Pharmaceuticals Recent Developments
11.2 Novartis
11.2.1 Novartis Corporation Information
11.2.2 Novartis Business Overview
11.2.3 Novartis Antisense Oligonucleotides (ASOs) Drugs Product Models, Descriptions and Specifications
11.2.4 Novartis Antisense Oligonucleotides (ASOs) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Novartis Antisense Oligonucleotides (ASOs) Drugs Sales by Product in 2024
11.2.6 Novartis Antisense Oligonucleotides (ASOs) Drugs Sales by Application in 2024
11.2.7 Novartis Antisense Oligonucleotides (ASOs) Drugs Sales by Geographic Area in 2024
11.2.8 Novartis Antisense Oligonucleotides (ASOs) Drugs SWOT Analysis
11.2.9 Novartis Recent Developments
11.3 Sanofi
11.3.1 Sanofi Corporation Information
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Antisense Oligonucleotides (ASOs) Drugs Product Models, Descriptions and Specifications
11.3.4 Sanofi Antisense Oligonucleotides (ASOs) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Sanofi Antisense Oligonucleotides (ASOs) Drugs Sales by Product in 2024
11.3.6 Sanofi Antisense Oligonucleotides (ASOs) Drugs Sales by Application in 2024
11.3.7 Sanofi Antisense Oligonucleotides (ASOs) Drugs Sales by Geographic Area in 2024
11.3.8 Sanofi Antisense Oligonucleotides (ASOs) Drugs SWOT Analysis
11.3.9 Sanofi Recent Developments
11.4 GSK
11.4.1 GSK Corporation Information
11.4.2 GSK Business Overview
11.4.3 GSK Antisense Oligonucleotides (ASOs) Drugs Product Models, Descriptions and Specifications
11.4.4 GSK Antisense Oligonucleotides (ASOs) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 GSK Antisense Oligonucleotides (ASOs) Drugs Sales by Product in 2024
11.4.6 GSK Antisense Oligonucleotides (ASOs) Drugs Sales by Application in 2024
11.4.7 GSK Antisense Oligonucleotides (ASOs) Drugs Sales by Geographic Area in 2024
11.4.8 GSK Antisense Oligonucleotides (ASOs) Drugs SWOT Analysis
11.4.9 GSK Recent Developments
11.5 Sarepta
11.5.1 Sarepta Corporation Information
11.5.2 Sarepta Business Overview
11.5.3 Sarepta Antisense Oligonucleotides (ASOs) Drugs Product Models, Descriptions and Specifications
11.5.4 Sarepta Antisense Oligonucleotides (ASOs) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Sarepta Antisense Oligonucleotides (ASOs) Drugs Sales by Product in 2024
11.5.6 Sarepta Antisense Oligonucleotides (ASOs) Drugs Sales by Application in 2024
11.5.7 Sarepta Antisense Oligonucleotides (ASOs) Drugs Sales by Geographic Area in 2024
11.5.8 Sarepta Antisense Oligonucleotides (ASOs) Drugs SWOT Analysis
11.5.9 Sarepta Recent Developments
11.6 Kastle
11.6.1 Kastle Corporation Information
11.6.2 Kastle Business Overview
11.6.3 Kastle Antisense Oligonucleotides (ASOs) Drugs Product Models, Descriptions and Specifications
11.6.4 Kastle Antisense Oligonucleotides (ASOs) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Kastle Recent Developments
11.7 Biogen
11.7.1 Biogen Corporation Information
11.7.2 Biogen Business Overview
11.7.3 Biogen Antisense Oligonucleotides (ASOs) Drugs Product Models, Descriptions and Specifications
11.7.4 Biogen Antisense Oligonucleotides (ASOs) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Biogen Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Antisense Oligonucleotides (ASOs) Drugs Industry Chain
12.2 Antisense Oligonucleotides (ASOs) Drugs Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Antisense Oligonucleotides (ASOs) Drugs Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Antisense Oligonucleotides (ASOs) Drugs Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Antisense Oligonucleotides (ASOs) Drugs Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Antisense Oligonucleotides (ASOs) Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
Lonis Pharmaceuticals
Novartis
Sanofi
GSK
Sarepta
Kastle
Biogen
List of Tables
 Table 1. Global Antisense Oligonucleotides (ASOs) Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Antisense Oligonucleotides (ASOs) Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Antisense Oligonucleotides (ASOs) Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Antisense Oligonucleotides (ASOs) Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Antisense Oligonucleotides (ASOs) Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Global Antisense Oligonucleotides (ASOs) Drugs Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
 Table 7. Global Antisense Oligonucleotides (ASOs) Drugs Sales by Region (2020-2025) & (K Units)
 Table 8. Global Antisense Oligonucleotides (ASOs) Drugs Sales by Region (2026-2031) & (K Units)
 Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 10. Global Antisense Oligonucleotides (ASOs) Drugs Sales by Manufacturers (2020-2025) & (K Units)
 Table 11. Global Antisense Oligonucleotides (ASOs) Drugs Sales Share by Manufacturers (2020-2025)
 Table 12. Global Antisense Oligonucleotides (ASOs) Drugs Revenue by Manufacturers (2020-2025) & (US$ Million)
 Table 13. Global Antisense Oligonucleotides (ASOs) Drugs Revenue Market Share by Manufacturers (2020-2025)
 Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 15. Global Antisense Oligonucleotides (ASOs) Drugs by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense Oligonucleotides (ASOs) Drugs as of 2024)
 Table 16. Global Antisense Oligonucleotides (ASOs) Drugs Average Gross Margin (%) by Manufacturer (2020 VS 2024)
 Table 17. Global Antisense Oligonucleotides (ASOs) Drugs Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
 Table 18. Key Manufacturers Antisense Oligonucleotides (ASOs) Drugs Manufacturing Base and Headquarters
 Table 19. Global Antisense Oligonucleotides (ASOs) Drugs Market Concentration Ratio (CR5 and HHI)
 Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 22. Global Antisense Oligonucleotides (ASOs) Drugs Sales by Type (2020-2025) & (K Units)
 Table 23. Global Antisense Oligonucleotides (ASOs) Drugs Sales by Type (2026-2031) & (K Units)
 Table 24. Global Antisense Oligonucleotides (ASOs) Drugs Revenue by Type (2020-2025) & (US$ Million)
 Table 25. Global Antisense Oligonucleotides (ASOs) Drugs Revenue by Type (2026-2031) & (US$ Million)
 Table 26. Global Antisense Oligonucleotides (ASOs) Drugs ASP by Type (2020-2031) & (US$/Unit)
 Table 27. Technical Specifications by Key Product Type
 Table 28. Global Antisense Oligonucleotides (ASOs) Drugs Sales by Application (2020-2025) & (K Units)
 Table 29. Global Antisense Oligonucleotides (ASOs) Drugs Sales by Application (2026-2031) & (K Units)
 Table 30. Antisense Oligonucleotides (ASOs) Drugs High-Growth Sectors Demand CAGR (2024-2031)
 Table 31. Global Antisense Oligonucleotides (ASOs) Drugs Revenue by Application (2020-2025) & (US$ Million)
 Table 32. Global Antisense Oligonucleotides (ASOs) Drugs Revenue by Application (2026-2031) & (US$ Million)
 Table 33. Global Antisense Oligonucleotides (ASOs) Drugs ASP by Application (2020-2031) & (US$/Unit)
 Table 34. Top Customers by Region
 Table 35. Top Customers by Application
 Table 36. North America Antisense Oligonucleotides (ASOs) Drugs Growth Accelerators and Market Barriers
 Table 37. North America Antisense Oligonucleotides (ASOs) Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 38. North America Antisense Oligonucleotides (ASOs) Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 39. Europe Antisense Oligonucleotides (ASOs) Drugs Growth Accelerators and Market Barriers
 Table 40. Europe Antisense Oligonucleotides (ASOs) Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Europe Antisense Oligonucleotides (ASOs) Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 42. Asia-Pacific Antisense Oligonucleotides (ASOs) Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 43. Asia-Pacific Antisense Oligonucleotides (ASOs) Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 44. Asia-Pacific Antisense Oligonucleotides (ASOs) Drugs Growth Accelerators and Market Barriers
 Table 45. Southeast Asia Antisense Oligonucleotides (ASOs) Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Central and South America Antisense Oligonucleotides (ASOs) Drugs Investment Opportunities and Key Challenges
 Table 47. Central and South America Antisense Oligonucleotides (ASOs) Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 48. Middle East and Africa Antisense Oligonucleotides (ASOs) Drugs Investment Opportunities and Key Challenges
 Table 49. Middle East and Africa Antisense Oligonucleotides (ASOs) Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 50. Lonis Pharmaceuticals Corporation Information
 Table 51. Lonis Pharmaceuticals Description and Major Businesses
 Table 52. Lonis Pharmaceuticals Product Models, Descriptions and Specifications
 Table 53. Lonis Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 54. Lonis Pharmaceuticals Sales Value Proportion by Product in 2024
 Table 55. Lonis Pharmaceuticals Sales Value Proportion by Application in 2024
 Table 56. Lonis Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
 Table 57. Lonis Pharmaceuticals Antisense Oligonucleotides (ASOs) Drugs SWOT Analysis
 Table 58. Lonis Pharmaceuticals Recent Developments
 Table 59. Novartis Corporation Information
 Table 60. Novartis Description and Major Businesses
 Table 61. Novartis Product Models, Descriptions and Specifications
 Table 62. Novartis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 63. Novartis Sales Value Proportion by Product in 2024
 Table 64. Novartis Sales Value Proportion by Application in 2024
 Table 65. Novartis Sales Value Proportion by Geographic Area in 2024
 Table 66. Novartis Antisense Oligonucleotides (ASOs) Drugs SWOT Analysis
 Table 67. Novartis Recent Developments
 Table 68. Sanofi Corporation Information
 Table 69. Sanofi Description and Major Businesses
 Table 70. Sanofi Product Models, Descriptions and Specifications
 Table 71. Sanofi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 72. Sanofi Sales Value Proportion by Product in 2024
 Table 73. Sanofi Sales Value Proportion by Application in 2024
 Table 74. Sanofi Sales Value Proportion by Geographic Area in 2024
 Table 75. Sanofi Antisense Oligonucleotides (ASOs) Drugs SWOT Analysis
 Table 76. Sanofi Recent Developments
 Table 77. GSK Corporation Information
 Table 78. GSK Description and Major Businesses
 Table 79. GSK Product Models, Descriptions and Specifications
 Table 80. GSK Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 81. GSK Sales Value Proportion by Product in 2024
 Table 82. GSK Sales Value Proportion by Application in 2024
 Table 83. GSK Sales Value Proportion by Geographic Area in 2024
 Table 84. GSK Antisense Oligonucleotides (ASOs) Drugs SWOT Analysis
 Table 85. GSK Recent Developments
 Table 86. Sarepta Corporation Information
 Table 87. Sarepta Description and Major Businesses
 Table 88. Sarepta Product Models, Descriptions and Specifications
 Table 89. Sarepta Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 90. Sarepta Sales Value Proportion by Product in 2024
 Table 91. Sarepta Sales Value Proportion by Application in 2024
 Table 92. Sarepta Sales Value Proportion by Geographic Area in 2024
 Table 93. Sarepta Antisense Oligonucleotides (ASOs) Drugs SWOT Analysis
 Table 94. Sarepta Recent Developments
 Table 95. Kastle Corporation Information
 Table 96. Kastle Description and Major Businesses
 Table 97. Kastle Product Models, Descriptions and Specifications
 Table 98. Kastle Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 99. Kastle Recent Developments
 Table 100. Biogen Corporation Information
 Table 101. Biogen Description and Major Businesses
 Table 102. Biogen Product Models, Descriptions and Specifications
 Table 103. Biogen Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 104. Biogen Recent Developments
 Table 105. Key Raw Materials Distribution
 Table 106. Raw Materials Key Suppliers
 Table 107. Critical Raw Material Supplier Concentration (2024) & Risk Index
 Table 108. Milestones in Production Technology Evolution
 Table 109. Distributors List
 Table 110. Market Trends and Market Evolution
 Table 111. Market Drivers and Opportunities
 Table 112. Market Challenges, Risks, and Restraints
 Table 113. Research Programs/Design for This Report
 Table 114. Key Data Information from Secondary Sources
 Table 115. Key Data Information from Primary Sources


List of Figures
 Figure 1. Antisense Oligonucleotides (ASOs) Drugs Product Picture
 Figure 2. Global Antisense Oligonucleotides (ASOs) Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Cleave and Degrade Product Picture
 Figure 4. Splice Product Picture
 Figure 5. Global Antisense Oligonucleotides (ASOs) Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 6. Hospital
 Figure 7. Clinic
 Figure 8. Antisense Oligonucleotides (ASOs) Drugs Report Years Considered
 Figure 9. Global Antisense Oligonucleotides (ASOs) Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 10. Global Antisense Oligonucleotides (ASOs) Drugs Revenue (2020-2031) & (US$ Million)
 Figure 11. Global Antisense Oligonucleotides (ASOs) Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 12. Global Antisense Oligonucleotides (ASOs) Drugs Revenue Market Share by Region (2020-2031)
 Figure 13. Global Antisense Oligonucleotides (ASOs) Drugs Sales (2020-2031) & (K Units)
 Figure 14. Global Antisense Oligonucleotides (ASOs) Drugs Sales (CAGR) by Region (2020-2031) (K Units)
 Figure 15. Global Antisense Oligonucleotides (ASOs) Drugs Sales Market Share by Region (2020-2031)
 Figure 16. Top 5 and Top 10 Manufacturers Antisense Oligonucleotides (ASOs) Drugs Sales Volume Market Share in 2024
 Figure 17. Global Antisense Oligonucleotides (ASOs) Drugs Revenue Market Share Ranking (2024)
 Figure 18. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 19. Cleave and Degrade Revenue Market Share by Manufacturer in 2024
 Figure 20. Splice Revenue Market Share by Manufacturer in 2024
 Figure 21. Global Antisense Oligonucleotides (ASOs) Drugs Sales Market Share by Type (2020-2031)
 Figure 22. Global Antisense Oligonucleotides (ASOs) Drugs Revenue Market Share by Type (2020-2031)
 Figure 23. Global Antisense Oligonucleotides (ASOs) Drugs Sales Market Share by Application (2020-2031)
 Figure 24. Global Antisense Oligonucleotides (ASOs) Drugs Revenue Market Share by Application (2020-2031)
 Figure 25. North America Antisense Oligonucleotides (ASOs) Drugs Sales YoY (2020-2031) & (K Units)
 Figure 26. North America Antisense Oligonucleotides (ASOs) Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 27. North America Top 5 Manufacturers Antisense Oligonucleotides (ASOs) Drugs Sales Revenue (US$ Million) in 2024
 Figure 28. North America Antisense Oligonucleotides (ASOs) Drugs Sales Volume (K Units) by Type (2020- 2031)
 Figure 29. North America Antisense Oligonucleotides (ASOs) Drugs Sales Revenue (US$ Million) by Type (2020 - 2031)
 Figure 30. North America Antisense Oligonucleotides (ASOs) Drugs Sales Volume (K Units) by Application (2020-2031)
 Figure 31. North America Antisense Oligonucleotides (ASOs) Drugs Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 32. US Antisense Oligonucleotides (ASOs) Drugs Revenue (2020-2031) & (US$ Million)
 Figure 33. Canada Antisense Oligonucleotides (ASOs) Drugs Revenue (2020-2031) & (US$ Million)
 Figure 34. Mexico Antisense Oligonucleotides (ASOs) Drugs Revenue (2020-2031) & (US$ Million)
 Figure 35. Europe Antisense Oligonucleotides (ASOs) Drugs Sales YoY (2020-2031) & (K Units)
 Figure 36. Europe Antisense Oligonucleotides (ASOs) Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 37. Europe Top 5 Manufacturers Antisense Oligonucleotides (ASOs) Drugs Sales Revenue (US$ Million) in 2024
 Figure 38. Europe Antisense Oligonucleotides (ASOs) Drugs Sales Volume (K Units) by Type (2020-2031)
 Figure 39. Europe Antisense Oligonucleotides (ASOs) Drugs Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 40. Europe Antisense Oligonucleotides (ASOs) Drugs Sales Volume (K Units) by Application (2020-2031)
 Figure 41. Europe Antisense Oligonucleotides (ASOs) Drugs Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 42. Germany Antisense Oligonucleotides (ASOs) Drugs Revenue (2020-2031) & (US$ Million)
 Figure 43. France Antisense Oligonucleotides (ASOs) Drugs Revenue (2020-2031) & (US$ Million)
 Figure 44. U.K. Antisense Oligonucleotides (ASOs) Drugs Revenue (2020-2031) & (US$ Million)
 Figure 45. Italy Antisense Oligonucleotides (ASOs) Drugs Revenue (2020-2031) & (US$ Million)
 Figure 46. Russia Antisense Oligonucleotides (ASOs) Drugs Revenue (2020-2031) & (US$ Million)
 Figure 47. Asia-Pacific Antisense Oligonucleotides (ASOs) Drugs Sales YoY (2020-2031) & (K Units)
 Figure 48. Asia-Pacific Antisense Oligonucleotides (ASOs) Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 49. Asia-Pacific Top 8 Manufacturers Antisense Oligonucleotides (ASOs) Drugs Sales Revenue (US$ Million) in 2024
 Figure 50. Asia-Pacific Antisense Oligonucleotides (ASOs) Drugs Sales Volume (K Units) by Type (2020- 2031)
 Figure 51. Asia-Pacific Antisense Oligonucleotides (ASOs) Drugs Sales Revenue (US$ Million) by Type (2020- 2031)
 Figure 52. Asia-Pacific Antisense Oligonucleotides (ASOs) Drugs Sales Volume (K Units) by Application (2020-2031)
 Figure 53. Asia-Pacific Antisense Oligonucleotides (ASOs) Drugs Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 54. Indonesia Antisense Oligonucleotides (ASOs) Drugs Revenue (2020-2031) & (US$ Million)
 Figure 55. Japan Antisense Oligonucleotides (ASOs) Drugs Revenue (2020-2031) & (US$ Million)
 Figure 56. South Korea Antisense Oligonucleotides (ASOs) Drugs Revenue (2020-2031) & (US$ Million)
 Figure 57. China Taiwan Antisense Oligonucleotides (ASOs) Drugs Revenue (2020-2031) & (US$ Million)
 Figure 58. India Antisense Oligonucleotides (ASOs) Drugs Revenue (2020-2031) & (US$ Million)
 Figure 59. Central and South America Antisense Oligonucleotides (ASOs) Drugs Sales YoY (2020-2031) & (K Units)
 Figure 60. Central and South America Antisense Oligonucleotides (ASOs) Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 61. Central and South America Top 5 Manufacturers Antisense Oligonucleotides (ASOs) Drugs Sales Revenue (US$ Million) in 2024
 Figure 62. Central and South America Antisense Oligonucleotides (ASOs) Drugs Sales Volume (K Units) by Type (2021-2031)
 Figure 63. Central and South America Antisense Oligonucleotides (ASOs) Drugs Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 64. Central and South America Antisense Oligonucleotides (ASOs) Drugs Sales Volume (K Units) by Application (2020-2031)
 Figure 65. Central and South America Antisense Oligonucleotides (ASOs) Drugs Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 66. Brazil Antisense Oligonucleotides (ASOs) Drugs Revenue (2020-2025) & (US$ Million)
 Figure 67. Argentina Antisense Oligonucleotides (ASOs) Drugs Revenue (2020-2025) & (US$ Million)
 Figure 68. Middle East, and Africa Antisense Oligonucleotides (ASOs) Drugs Sales YoY (2020-2031) & (K Units)
 Figure 69. Middle East and Africa Antisense Oligonucleotides (ASOs) Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 70. Middle East and Africa Top 5 Manufacturers Antisense Oligonucleotides (ASOs) Drugs Sales Revenue (US$ Million) in 2024
 Figure 71. Middle East and Africa Antisense Oligonucleotides (ASOs) Drugs Sales Volume (K Units) by Type (2021-2031)
 Figure 72. South America Antisense Oligonucleotides (ASOs) Drugs Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 73. Middle East and Africa Antisense Oligonucleotides (ASOs) Drugs Sales Volume (K Units) by Application (2020-2031)
 Figure 74. Middle East and Africa Antisense Oligonucleotides (ASOs) Drugs Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 75. GCC Countries Antisense Oligonucleotides (ASOs) Drugs Revenue (2020-2025) & (US$ Million)
 Figure 76. Turkey Antisense Oligonucleotides (ASOs) Drugs Revenue (2020-2025) & (US$ Million)
 Figure 77. Egypt Antisense Oligonucleotides (ASOs) Drugs Revenue (2020-2025) & (US$ Million)
 Figure 78. South Africa Antisense Oligonucleotides (ASOs) Drugs Revenue (2020-2025) & (US$ Million)
 Figure 79. Antisense Oligonucleotides (ASOs) Drugs Industry Chain Mapping
 Figure 80. Regional Antisense Oligonucleotides (ASOs) Drugs Manufacturing Base Distribution (%)
 Figure 81. Global Antisense Oligonucleotides (ASOs) Drugs Production Market Share by Region (2020-2031)
 Figure 82. Antisense Oligonucleotides (ASOs) Drugs Production Process
 Figure 83. Regional Antisense Oligonucleotides (ASOs) Drugs Production Cost Structure
 Figure 84. Channels of Distribution (Direct Vs Distribution)
 Figure 85. Bottom-up and Top-down Approaches for This Report
 Figure 86. Data Triangulation
 Figure 87. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS

Global Antisense Oligonucleotide Service Market Research Report 2025
Global Antisense Oligonucleotides Market Research Report 2024
Global ASO based Drug Market Research Report 2024
Global Antisense Oligonucleotides based Therapeutics Market Research Report 2024
Global Antisense ODN Market Research Report 2024
Global Antisense Oligonucleotides ASO Therapy Market Research Report 2024
Global Antisense Oligonucleotide Therapy for the Nervous System Market Research Report 2024
Global Antisense Oligonucleotides ASO Drug Market Research Report 2024
Global Antisense oligonucleotides ASO Drug and siRNA Drug Market Research Report 2024
Antisense Oligonucleotide ASO Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Oligonucleotide Oligo Drugs Market Research Report 2024
Global Oligonucleotide Drugs ONs Market Research Report 2025
Global CNS Specific Antisense Oligonucleotides Market Research Report 2024
Global Antisense Oligonucleotides Drugs for ATTR Market Research Report 2024
Global Low Molecular Weight Nucleic Acid Drugs Market Research Report 2025
Global Nucleic Acid Drugs Market Research Report 2025
DNA RNA Oligonucleotides Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Antisense and RNAi Therapeutics Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Oligonucleotides Market Insights Forecast to 2030
Global Oligonucleotide Therapeutics Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions